Hydrochlorothiazide for Calcium Kidney Stone Prevention
Hydrochlorothiazide is appropriate for preventing recurrent calcium kidney stones, but only after increased fluid intake fails, and the evidence supporting its efficacy has been significantly challenged by recent high-quality trials.
Stepwise Approach to Prevention
First-Line: Fluid Intake
Start all patients with increased fluid intake spread throughout the day to achieve at least 2 L of urine output daily 1. This is the foundation of stone prevention and must be attempted before pharmacologic therapy.
Second-Line: Pharmacologic Therapy
Only proceed to medication if fluid intake fails to prevent stone recurrence. The 2014 ACP guidelines recommend thiazide diuretics as one of three equally acceptable monotherapy options (thiazides, citrate, or allopurinol) for preventing recurrent calcium stones 1.
Critical Evidence Update: The NOSTONE Trial Challenge
The 2023 NOSTONE trial—the largest and highest quality study to date—found no significant benefit of hydrochlorothiazide at any dose (12.5 mg, 25 mg, or 50 mg daily) compared to placebo 2. This landmark trial followed 416 patients for a median of 2.9 years and showed:
- Placebo group: 59% recurrence rate
- HCTZ 12.5 mg: 59% recurrence (rate ratio 1.33)
- HCTZ 25 mg: 56% recurrence (rate ratio 1.24)
- HCTZ 50 mg: 49% recurrence (rate ratio 0.92, not statistically significant)
- No dose-response relationship (P = 0.66)
A 2025 network meta-analysis confirmed these findings, concluding that current evidence does not support routine prescription of thiazides for kidney stone prevention 3. A 2024 comprehensive meta-analysis similarly found no significant benefit of thiazide monotherapy over placebo 4.
Dosing Recommendations (When Used)
Despite the NOSTONE trial's negative findings, if you choose to prescribe hydrochlorothiazide based on the older guideline recommendations:
The evidence-based dose is 50 mg daily 1. The ACP guidelines explicitly state: "the available evidence evaluated higher doses of thiazides (hydrochlorothiazide, 50 mg; chlorthalidone, 25 or 50 mg; indapamide, 2.5 mg)" and note that "the use of lower doses of thiazides is associated with fewer adverse effects, but their effectiveness in preventing stone recurrence compared with higher doses is not known" 1.
Alternative Thiazide Options
- Chlorthalidone 25-50 mg daily: May be more effective than hydrochlorothiazide at reducing urinary calcium (41% reduction vs 21% with HCTZ 25 mg) 5
- Indapamide 2.5 mg daily 1
Treatment Duration
A 2025 meta-analysis suggests treatment for 36 months is necessary to demonstrate efficacy, with shorter durations (≤12 months) showing no statistical benefit 6.
Monitoring Requirements
Baseline Assessment
- 24-hour urine calcium (though the guidelines note insufficient evidence that knowing stone composition or urine chemistry predicts treatment effectiveness) 1
- Serum potassium, creatinine, glucose, uric acid
- Blood pressure
Follow-up Monitoring
- Serum potassium: Monitor regularly for hypokalemia (decreased by 0.5 mEq/L in trials) 5
- Serum creatinine: Watch for increases >150% of baseline 2
- Glucose: Screen for new-onset diabetes mellitus 2
- Uric acid: Monitor for gout 2
- 24-hour urine calcium: Consider repeat collection 30-180 days after initiation 7
Adverse Effects to Anticipate
The NOSTONE trial demonstrated that adverse events were more common with hydrochlorothiazide than placebo 2:
- Hypokalemia
- New-onset diabetes mellitus
- Gout
- Skin allergy
- Elevated creatinine
Who May Benefit Most
Patients with higher baseline urinary calcium appear to achieve greater absolute reductions in urinary calcium with thiazides 7. A 2026 study showed that higher baseline urine calcium was associated with greater mean absolute and percentage urine calcium reductions (P<0.001), and higher thiazide doses produced larger reductions 7. This suggests that if thiazides are used, they should be reserved for patients with documented hypercalciuria, though even this remains controversial given the NOSTONE results 8.
Critical Caveats
The evidence base has fundamentally shifted: While 2014 ACP guidelines support thiazides based on moderate-quality evidence, the 2023 NOSTONE trial—the largest and most rigorous study—contradicts this recommendation 2, 4.
No evidence for combination therapy: Combination therapy with thiazides plus other agents was not more beneficial than monotherapy 1.
Bone mineral density: A 2025 post-hoc analysis of NOSTONE found no benefit of hydrochlorothiazide on preserving bone mineral density over 3 years 9.
Contraindications per FDA labeling: Avoid in patients with anuria or hypersensitivity to sulfonamide-derived drugs 10.
Clinical Bottom Line
Given the conflicting evidence, adopt a restrictive approach: Use hydrochlorothiazide only in highly selected patients with recurrent calcium stones who have failed aggressive fluid intake optimization and who have documented hypercalciuria. If prescribed, use 50 mg daily (the only dose with any supporting evidence from older trials), monitor closely for adverse effects, and consider alternative agents (citrate or allopurinol) as equally valid first-line pharmacologic options per ACP guidelines 1. The high unmet medical need for effective kidney stone prevention therapies remains 4.